Session: SUN 432-458-Thyroid Autoimmunity
Poster Board SUN-452
We studied 93 consecutive children (75 females and 18 males) with chronic lymphocytic thyroiditis (CLT) (n=86) or Graves’ disease (GD) (n=7). All patients were from the Pediatric Endocrinology Unit and were admitted for AITD. The mean age at diagnosis of AITD was 10.2±3.9 yr, mean time at sampling was 12.1±4.6 yr . Among the 93 children 9 had celiac disease, 2 autoimmune gastritis, 2 alopecia, 2 vitiligo, 1 diabetes type 1 and autoimmune gastritis and 1 autoimmune piastrinopenia. Serum ANA detected by indirect immunofluorescence on HEp-2, antibodies against extractable nuclear antigen (ENA), anti-dsDNA, anti-cyclic citrullinated peptide antibodies (anti-CCP) and Rheumatoid Factor (RF) were determined in all patients. All children and parents were interviewed according to a standard questionnaire seeking signs and symptoms related to rheumatic diseases in children. Children with signs and/or symptoms were referred to the rheumatologist. Data were expressed as mean±standard deviation for continuous data.
We found 66 (71%) of 93 children positive for ANA, 4 (4.3%) for ENA , 1 (1.1%) for anti-dsDNA, and 3/93 (3.92%) for RF .We compared clinical and laboratory findings in ANA-positive children (n: 66, Group A), and ANA-negative children (n: 27 group B). Non significant differences were found about F/M ratio, age at diagnosis and age at inclusion in the study, TSH, abTPO and abTg levels, LT4 treatment. No differences were found between group A and group B about the presence of joint pain, joint swelling, morning stiffness, back pain, asthenia, Raynaud’s phenomenon, xerostomia, xeropthalmia, aftae, pleuritis, pericarditis.
This study confirmed ANA positivity in 71% of children with AITD. ANA positivity at the time of the study was not related with overt rheumathic diseases. However, because the positivity of ANA can occur even many years before the onset of systemic autoimmune diseases (i.e. SLE), a prospective study is warranted in these patients.
Nothing to Disclose: MS, IT, CS, IP, FC
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters